BCL2L1 and familial pancreatic carcinoma: Further, CRISPR knock-out screening facilitated the identification of BCL2L1 (BCL-XL gene) as a possible target in order to increase sensibility for gemcitabine in pancreatic cancer treatment [63], and TP53 and BAX as key genes in venetoclax-resistance in acute myeloid leukemia cells [64].